Foulkes started her commercial career in consultancy with McKinsey & Company in 1995 before moving to help establish Nexan Ltd, a medical device start-up. She also worked in commercial roles at Acambis PLC, a vaccine development company, and Cangene Corporation, an immune therapeutics company where she led strategic business development from 2007-2011. She was also the senior director of business development at Liminal BioSciences, a Nasdaq listed multinational company focusing on rare diseases, from 2016.
“Lindsey will play a key role in ensuring that we deliver on the key strategic goals that we set out at the time of our recent IPO. She brings extensive experience from across the innovative healthcare sector which will significantly strengthen our commercial and operational capabilities as we advance our internal proprietary pipeline and further expand our partnered portfolio,” said Sarah Howell, the chief executive officer of Arecor.
Lindsey Foulkes said she was excited to be joining the company.
“Arecor’s innovative Arestat technology has been validated through multiple partnerships with major pharmaceutical and biotechnology companies, as well as through the best-in-class clinical data achieved for its lead insulin programme AT247,” she said.